A living therapeutic patch to heal damaged gut lining
Anna Duraj–Thatte, PhD
AMOUNT AWARDED: $50,000
ABOUT TANTU THERAPEUTICS:
Tantu Therapeutics is developing innovative microbe-based therapeutics expressed and delivered to the site of intestinal lesions to treat Inflammatory Bowel Disease (IBDJ and other gastrointestinal (GI) diseases without systemic side effects.
1.6 million Americans suffer from debilitating and poorly treated IBD diseases. Existing treatment do not achieve mucosal healing and 1/3 of patients still require surgery.
Tantu Therapeutics will provide an orally administered, live inflammatory factors directly into the diseased sites, resulting in improved gut barrier function and faster mucosal healing as well as extend remission to avoid the surgery in most patients.
Anna Duraj-Thatte, PhD
Co-founder and Scientific Lead
John Tagliamonte, MBA
Co-founder and Business Lead
Neel Joshi, PhD
Co-founder and Scientific Advisor